Drug company payments to General Practices in England: Cross-sectional and social network analysis.

ABSTRACT: Although there has been extensive research on pharmaceutical industry payments to healthcare professionals, healthcare organisations with key roles in health systems have received little attention. We seek to contribute to addressing this gap in research by examining drug company payments to General Practices in England in 2015. We combine a publicly available payments database managed by the pharmaceutical industry with datasets covering key practice characteristics. We find that practices were an important target of company payments, receiving £2,726,018, equivalent to 6.5% of the value of payments to all healthcare organisations in England. Payments to practices were highly concentrated and specific companies were also highly dominant. The top 10 donors and the top 10 recipients amassed

SUBMITTER: Saghy E 

PROVIDER: S-EPMC8651134 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature